Heart Failure With Preserved Ejection Fraction Clinical Trial
Official title:
Exploration of Dyspnea at Non-high BNP
Patients with unexplained stress dyspnea ( ≥ stage 2 NYHA), no significant underlying lung
disease, with an ejection fraction > 50%, normal resting filling pressures, NTproBNP < 220
pg/ml in < 75 years, and < 450 pg/ml in ≥ 75 years will be studied with stress
echocardiography and cardiometabolic stress test (VO2). These patients may have abnormal
adaptation during exercise, suggesting that chronic symptoms may be related to a heart
failure with preserved ejection fraction (HFPEF). More accurate and earlier diagnosis of
HFPEF using stress echocardiography and VO2 may better manage stress dyspnea in patients and
prevent progression of HFPEF.
A clinical assessment will be offered to people with unexplained stress dyspnea. The
procedures and products used in this study are usually used as part of HFpEF's diagnostic
strategy. During this assessment, carried out on an outpatient basis, an anamnesis
collection, a cardiovascular clinical examination, an evaluation of dyspnea by the NYHA
functional class and by 2 questionnaires, an electrocardiogram will be carried out, a
6-minute walk test, a biological blood test, a trans thoracic rest and stress cardiac
ultrasound, respiratory functional tests (with diffusion capacity of lung for carbon monoxide
(DLCO) and blood gas), and a metabolic stress test. A follow-up at 1 and 2 years is planned
(visit, sampling and resting echocardiography).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
| Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
| Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
| Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
| Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
| Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
| Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
| Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
| Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
| Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
| Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
| Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
| Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
| Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
| Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
| Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
| Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
| Withdrawn |
NCT05322616 -
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
|
Phase 1 | |
| Not yet recruiting |
NCT06309537 -
Chemoreflex Sensitivity in HFpEF
|